Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
First Claim
1. A method of providing rapid treatment of migraine, said method comprising administering a total dose of dihydroergotamine mesylate to a human suffering from migraine via pulmonary administration, wherein the dihydroergotamine mesylate is administered at a rate that provides:
- a mean peak plasma concentration (Cmax) of dihydroergotamine of less than 40,000 pg/ml within a mean time to Cmax (Tmax) that is less than 20 minutes after administration; and
a Cmax of 8′
-OH dihydroergotamine of less than 1,000 pg/ml, wherein the total dose of dihydroergotamine mesylate that is administered ranges from 0.1 to 10 mg per migraine.
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.
-
Citations
14 Claims
-
1. A method of providing rapid treatment of migraine, said method comprising administering a total dose of dihydroergotamine mesylate to a human suffering from migraine via pulmonary administration, wherein the dihydroergotamine mesylate is administered at a rate that provides:
-
a mean peak plasma concentration (Cmax) of dihydroergotamine of less than 40,000 pg/ml within a mean time to Cmax (Tmax) that is less than 20 minutes after administration; and a Cmax of 8′
-OH dihydroergotamine of less than 1,000 pg/ml, wherein the total dose of dihydroergotamine mesylate that is administered ranges from 0.1 to 10 mg per migraine. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of providing rapid treatment of migraine, said method comprising administering a unit dose of dihydroergotamine mesylate to a human suffering from migraine via pulmonary administration, wherein the dihydroergotamine mesylate is administered at a rate that provides:
-
a mean time to Cmax (Tmax) of dihydroergotamine that is less than 20 minutes after administration, and a mean area under a curve of a concentration of dihydroergotamine in systemic circulation versus time (AUC) is within 75% of a comparable intravenous (IV) delivered dose; and a Cmax of 8′
-OH dihydroergotamine of less than 1,000 pg/ml, wherein the unit dose of dihydroergotamine mesylate is less than 2.0 mg.
-
Specification